 |
|
 |
 |
|
TUESDAY,
AUGUST 7, 2007
Advances
in Immunotherapy
for Malignant
Melanoma
A
complimentary
dinner meeting
Chapel Hill, North
Carolina
Chair:
F. Stephen Hodi
Jr., MD
Dana Farber Cancer
Institute
Boston, Massachusetts
Click
here to register
for this program
|
 |
|
F A C
U L T
Y |
 |
|
|
F. Stephen Hodi Jr., MD
Dana
Farber Cancer Institute
Boston,
Massachusetts |
David W. Ollila, MD
UNC
Lineberger Comprehensive Cancer Center
Chapel
Hill, North Carolina
|
William H. Sharfman, MD
Sidney
Kimmel
Comprehensive
Cancer
Center
at
Johns
Hopkins
Baltimore,
Maryland
|
|
|
|
S C I
E N T
I F I
C
A G E
N D A
|
|
|
6:00pm
Registration
and reception
6:30 pm
Introduction
to the
biology
of
melanoma
F.
Stephen Hodi Jr., MD
6:45
pm
Immunotherapy:
Harnessing
the immune
response
to cancer
William
H. Sharfman, MD
7:15 pm
Overcoming
immunologic
tolerance
to
melanoma:
Targeting
CTLA-4
F.
Stephen Hodi Jr., MD
7:45
pm
Enhancing
the immune
response
to melanoma:
Vaccines
and other
novel biologics to stimulate and target the immune response
David
W. Ollila, MD
8:15 pm
Question
and answer
session
8:30 pm
Adjourn |
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex
Accreditation
Services,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex
Accreditation
Services,
LLC
designates
this
educational
activity
for
a
maximum
2.0
of
AMA
PRA
Category
1
Credit(s)TM.
Physicians
should
only
claim
credit
commensurate
with
the
extent
of
their
participation
in
the
activity.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
specifically
designed
for
medical
oncologists,
dermatologists,
and
other
physicians,
physicians-in-training,
and
healthcare
professionals
interested
in
and/or
involved
in
the
care
of
patients
with
melanoma
and
its
consequences.
No
specialized
knowledge
or
skill
other
than
general
familiarity
with
internal
medicine,
oncology,
or
dermatology
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After
successfully
completing
this
educational
activity,
participants
should
be
able
to:
- Describe
the
basic concepts
of immunotherapy
and how
each type
can be
used as
a treatment modality in
oncology
-
Discuss
the
role
immune
tolerance
plays
in
allowing
the
growth
and
spread
of
cancer
cells
-
Explain
the
specific
role
of
CTLA-4
in
maintaining
immune
tolerance
and
how
inhibiting
its
function
can
be
used
in
the
treatment
of
malignant
melanoma
-
Compare
and
contrast
emerging
biological
agents,
primarily
vaccines
and
cytokines,
that
are
used
to
stimulate
and
target
a
patient’s
own
immune
response
against
a
tumor
and
are
currently
in
trials
for
use
against
melanoma
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here
to
register
for
this
program
You may register online by August 6,
2007
or by calling Imedex at +1 (678) 242 0906. Registration
confirmations
will be issued before the meeting. This is a complimentary
dinner meeting and space
is limited. To confirm your attendance, please register by August 6, 2007.
|
|
|
|
G
E N E
R A L
I N F
O R M
A T I
O N |
|
|
|
Meeting
Location
The
Siena
Hotel
The
Lombardi
Room
1505
East
Franklin
Street
Chapel
Hill,
North
Carolina
27514
Tel:
+1
(919)
929-4000
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex Accreditation
Services, LLC.
All rights reserved.
Reproduction in
whole or part
is prohibited
without prior
written consent
from Imedex and
contributing faculty.
|
